ER/PgR expression | HER2 phenotypes | Breast cancer type | Number of patients | Total | ||
---|---|---|---|---|---|---|
Binary classification | semiquantitative expression | Ki-67 < =20% | Ki-67 > 20% | |||
ER + PgR+ | “negative” | 0+ | Luminal A/B1 | 248 | 90 | 338 |
1+ | 165 | 68 | 233 | |||
2+ | 44 | 19 | 63 | |||
“overexpressed” | 3+ | Luminal B2 | 82 | 83 | 165 | |
Total of patients with ER & PgR positive tumors | 539 | 260 | 799 | |||
ER + PgR- | “negative” | 0+ | Luminal A/B1 | 15 | 10 | 25 |
1+ | 14 | 12 | 26 | |||
2+ | 4 | 3 | 7 | |||
“overexpressed” | 3+ | Luminal B2 | 13 | 20 | 33 | |
Total of patients with ER positive & PgR negative tumors | 46 | 45 | 91 | |||
ER-PgR+ | “negative” | 0+ | Luminal A/B1 | 1 | 3 | 4 |
1+ | 3 | 2 | 5 | |||
2+ | 2 | 0 | 2 | |||
“overexpressed” | 3+ | Luminal B2 | 0 | 0 | 0 | |
Total of patients with ER negative & PgR positive tumors | 6 | 5 | 11 | |||
ER-PgR- | “negative” | 0+ | triple-negative | 20 | 86 | 106 |
1+ | 9 | 31 | 40 | |||
2+ | 2 | 6 | 8 | |||
“overexpressed” | 3+ | pure HER2 | 27 | 98 | 125 | |
Total of patients with ER & PgR negative tumors | 58 | 221 | 279 | |||
Total of all patients | 649 | 531 | 1180 |